Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study in patients with chronic stable coronary artery disease treatable
by percutaneous coronary intervention (PCI) is to evaluate the long-term efficacy and safety
of the orally taken selective I(f)-inhibitor Ivabradine (Procoralan®, Servier Switzerland)
with regard to the promotion of collateral growth.